Patents by Inventor Michael William Pride

Michael William Pride has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11872274
    Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
    Type: Grant
    Filed: March 6, 2021
    Date of Patent: January 16, 2024
    Assignee: Pfizer Inc.
    Inventors: Emilio Anthony Emini, Wendy Jo Watson, Avvari Krishna Prasad, Mingming Han, Jin-Hwan Kim, Jianxin Gu, Yu-Ying Yang, Rajesh Kumar Kainthan, David Cooper, Michael William Pride, Kathrin Ute Jansen
  • Publication number: 20240000912
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 15, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.
    Type: Application
    Filed: November 1, 2021
    Publication date: January 4, 2024
    Inventors: Annaliesa Sybil Anderson, Seema Shridhar Gangolli, Kathrin Ute Jansen, Avvari Krishna Prasad, Michael William Pride, Ingrid Lea Scully, Wendy Jo Watson
  • Publication number: 20230218735
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
    Type: Application
    Filed: June 17, 2021
    Publication date: July 13, 2023
    Inventors: Annaliesa Sybil Anderson, Alexey Vyacheslavovitch Gribenko, William Carl Gruber, Kathrin Ute Jansen, Lakshmi Khandke, Nicholas Randolph Everard Kitchin, Jody Lawrence, Yahong Peng, Michael William Pride, Christopher Frederick Webber, Sabine Susanne Wellnitz, Zhuobiao Yi
  • Publication number: 20230190907
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
    Type: Application
    Filed: July 15, 2022
    Publication date: June 22, 2023
    Inventors: David Cooper, Kathrin Ute Jansen, Michael William Pride
  • Patent number: 11413344
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: August 16, 2022
    Assignee: Pfizer Inc.
    Inventors: David Cooper, Kathrin Ute Jansen, Michael William Pride
  • Publication number: 20220160859
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
    Type: Application
    Filed: March 30, 2020
    Publication date: May 26, 2022
    Inventors: Kathrin Ute Jansen, Annaliesa Sybil Anderson, Alexey Vyacheslavovitch Gribenko, Nicholas Randolph Everard Kitchin, Paul Liberator, Michael William Pride, Christopher Frederick Webber
  • Publication number: 20210393764
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
    Type: Application
    Filed: September 1, 2021
    Publication date: December 23, 2021
    Inventors: David Cooper, Kathrin Ute Jansen, Michael William Pride
  • Patent number: 11160855
    Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: November 2, 2021
    Assignee: Pfizer Inc.
    Inventors: Emilio Anthony Emini, Wendy Jo Watson, Avvari Krishna Prasad, Mingming Han, Jin-Hwan Kim, Jianxin Gu, Yu-ying Yang, Rajesh Kumar Kainthan, David Cooper, Michael William Pride, Kathrin Ute Jansen
  • Patent number: 11135279
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: October 5, 2021
    Assignee: Pfizer Inc.
    Inventors: David Cooper, Kathrin Ute Jansen, Michael William Pride
  • Patent number: 11090375
    Abstract: The present invention relates to new immunogenic compositions comprising conjughated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: August 17, 2021
    Assignee: Pfizer Inc.
    Inventors: Emilio Anthony Emini, Wendy Jo Watson, Avvari Krishna Prasad, Mingming Han, Jin-Hwan Kim, Jianxin Gu, Yu-ying Yang, Rajesh Kumar Kainthan, David Cooper, Michael William Pride, Kathrin Ute Jansen
  • Publication number: 20210196810
    Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
    Type: Application
    Filed: March 6, 2021
    Publication date: July 1, 2021
    Applicant: Pfizer Inc.
    Inventors: Emilio Anthony Emini, Wendy Jo Watson, Avvari Krishna Prasad, Mingming Han, Jin-Hwan Kim, Jianxin Gu, Yu-ying Yang, Rajesh Kumar Kainthan, David Cooper, Michael William Pride, Kathrin Ute Jansen
  • Publication number: 20200405837
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 10A and 39, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.
    Type: Application
    Filed: August 24, 2020
    Publication date: December 31, 2020
    Inventors: Fiona Laichu Lin, Viliam Pavliak, Michael William Pride, Shite Sebastian
  • Publication number: 20200306357
    Abstract: The present invention relates to new immunogenic compositions comprising conjughated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 1, 2020
    Inventors: Emilio Anthony Emini, Wendy Jo Watson, Avvari Krishna Prasad, Mingming Han, Jin-Hwan Kim, Jianxin Gu, Yu-ying Yang, Rajesh Kumar Kainthan, David Cooper, Michael William Pride, Kathrin Ute Jansen
  • Patent number: 10786561
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 10A and 39, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: September 29, 2020
    Assignee: Pfizer Inc.
    Inventors: Fiona Laichu Lin, Viliam Pavliak, Michael William Pride, Shite Sebastian
  • Publication number: 20200237890
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.
    Type: Application
    Filed: April 9, 2020
    Publication date: July 30, 2020
    Inventors: David Cooper, Kathrin Ute Jansen, Michael William Pride
  • Patent number: 10653764
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention thereforerelates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: May 19, 2020
    Assignee: Pfizer Inc.
    Inventors: David Cooper, Kathrin Ute Jansen, Michael William Pride
  • Publication number: 20190343946
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
    Type: Application
    Filed: January 5, 2018
    Publication date: November 14, 2019
    Inventors: David Cooper, Kathrin Ute Jansen, Michael William Pride
  • Publication number: 20190000952
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 10A and 39, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
    Type: Application
    Filed: November 7, 2016
    Publication date: January 3, 2019
    Inventors: FIONA LAICHU LIN, VILIAM PAVLIAK, MICHAEL WILLIAM PRIDE, SHITE SEBASTIAN
  • Publication number: 20180099039
    Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
    Type: Application
    Filed: October 6, 2016
    Publication date: April 12, 2018
    Inventors: Emilio Anthony Emini, Wendy Jo Watson, Avvari Krishna Prasad, Mingming Han, Jin-Hwan Kim, Jianxin Gu, Yu-ying Yang, Rajesh Kumar Kainthan, David Cooper, Michael William Pride, Kathrin Ute Jansen
  • Publication number: 20180000922
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention thereforerelates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
    Type: Application
    Filed: January 5, 2016
    Publication date: January 4, 2018
    Applicant: Pfizer Inc.
    Inventors: David Cooper, Kathrin Ute Jansen, Michael William Pride